Ping Lu

Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial

Caicun Zhou, Gongyan Chen, Yunchao Huang et al. · Journal of Thoracic Oncology · 2023 · 69 citations · Full text

Medicine, Oncology, Pharmacology +11

Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report

Xiaodi Zhang, Yuying Guo, Yinghua Ji et al. · Cell Transplantation · 2022 · 58 citations · Full text

Life Sciences, Immunology, Oncology +17

ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC).

Jie Wang, Jianchun Duan, Yuping Sun et al. · Journal of Clinical Oncology · 2024 · 24 citations

Medicine, Oncology, Pharmacology +9

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study

Caicun Zhou, Gongyan Chen, Yunchao Huang et al. · Journal for ImmunoTherapy of Cancer · 2024 · 24 citations · Full text

Medicine, Oncology, Pharmacology +15

Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study

Xiangrui Meng, Junsheng Wang, Jin Xia et al. · European Journal of Cancer · 2024 · 18 citations

Medicine, Oncology, Pharmacology +17